According to the data of the trial released by Bharat Biotech, the Covaxin has been found to be 77.8 percent effective against the Coronavirus.
India’s indigenous vaccine maker Bharat Biotech has completed the third and final phase trial of Covaxin and has also released its results. Hyderabad-based Bharat Biotech said that it has analyzed the data from the final phase-3 and its vaccine has been found to be effective in severe patients of coronavirus and patients of delta variant.
According to the data of the trial released by Bharat Biotech, the indigenous vaccine has been found to be 77.8 percent effective against the Coronavirus in the final phase trial. At the same time, this vaccine has been found to be 65.2% effective against dangerous delta variants causing new concerns worldwide.
Citing pre-print data, Bharat Biotech said that its Covaxin is 77.8 percent effective against symptomatic corona patients. At the same time, Covaxin is 93.4 percent effective against serious patients of corona. At the same time, it is 65.2% effective against the delta variants of Coronavirus. Bharat Biotech has conducted this trial on 130 confirmed cases.
According to the analysis of its final-stage data, the company said that Covaxin is 63.6% effective against asymptomatic corona patients.
According to Bharat Biotech, the Covaxin trial was conducted in 25 different hospitals in the country. About 25800 volunteers were involved in this, who were in the age group of 18 to 98 years. People participating in the Phase III trial were given both doses of the vaccine i.e. a placebo.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
